

Date: 14.11.2018

To,  
The Secretary,  
The B.S.E Limited  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai - 400 001

**Sub: Submission of Un-Audited Standalone Financials Results of the Company and Limited Review Report as per Provisions of Regulation 30, 33 of SEBI (LODR) Regulations, 2015.**

Please find enclosed here with the following Documents in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015:

1. Financial Results: Un-Audited Standalone Financial Results of the company for the Second Quarter/Half Year ended 30<sup>th</sup> September, 2018.
2. Limited Review Report: A Certified Copy of the Limited Review Report on Standalone Financials for the Second Quarter/Half Year ended 30<sup>th</sup> September, 2018 by the Auditors.

This is for your Information and Necessary Records.

Thanking you  
For **TRIMURTHI LIMITED**



**Arun Kumar Bhangadia**  
Managing Director  
DIN: 00021024



**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956

Date: 14.11.2018

To,  
The Secretary,  
The B.S.E Limited  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai- 400 001

Sub: Outcome of the Board Meeting held on 14/11/2018 as per Regulation 30, 33 of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

The Board of Directors of the Company at its meeting held today, Wednesday, the 14<sup>th</sup> day of November, 2018 at Registered Office, have approved and taken on record the following:

1. The Board has considered and approved the minutes of the previous board meeting.
2. The Board has considered and approved the Unaudited Standalone Financial Results for the Second Quarter/Half Year ended 30<sup>th</sup> September, 2018 along with Limited Review Report issued by the Statutory Auditors of the Company in compliance with Indian Accounting Standards (Ind-AS), SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013.

There being no other matter meeting of the Board of Directors concluded with the vote of thanks.

The Meeting of the Board of Directors of the company commenced at 03.00 P.M. and Concluded at 04:00 PM

Request you to take same on records.

Thanking you  
for TRIMURTHI LIMITED

  
**Arun Kumar Bhangadia**  
Managing Director  
DIN: 00021024

**TRIMURTHI LIMITED**  
(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956





**TRIMURTHI LIMITED**  
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)  
4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad - 500095.  
**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS**  
**FOR THE QUARTER ENDED SEPTEMBER 2018**

**TRIMURTHI**  
GROUP

Rs. in Lakhs

PARTICULARS	QUARTER ENDED			HALF YEARLY ENDED	
	30.09.2018 (UNAUDITED)	30.06.2018 (UNAUDITED)	30.09.2017 (UNAUDITED)	30.09.2018 (UNAUDITED)	30.09.2017 (UNAUDITED)
<b>1. INCOME</b>					
INCOME FROM OPERATIONS	107.03	104.44	27.25	211.47	78.13
OTHER INCOME	1.54	0.86	0.05	2.41	2.16
<b>TOTAL INCOME</b>	<b>108.58</b>	<b>105.30</b>	<b>27.30</b>	<b>213.88</b>	<b>80.29</b>
<b>2. EXPENSES</b>					
PURCHASES	85.11	75.64	2.79	160.75	3.08
COST OF MATERIALS CONSUMED	-	-	-	-	-
MANUFACTURING EXPENSES	-	-	-	-	-
WORK IN PROGRESS AND STOCK IN TRADE	-	7.16	(0.53)	7.16	21.39
RENT	0.60	0.65	0.55	1.25	1.30
EMPLOYEE BENEFITS EXPENSE	8.48	6.22	5.47	14.70	11.28
FINANCE COSTS	-	-	-	-	-
DEPRECIATION AND AMORTISATION EXPENSES	2.99	3.02	4.01	6.01	7.70
OTHER EXPENSES	7.78	11.74	2.74	19.52	8.10
<b>TOTAL EXPENSES</b>	<b>104.96</b>	<b>104.44</b>	<b>15.03</b>	<b>209.39</b>	<b>52.85</b>
<b>3. PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE EXCEPTIONAL ITEMS (1-2)</b>	<b>3.62</b>	<b>0.87</b>	<b>12.27</b>	<b>4.49</b>	<b>27.44</b>
<b>4. EXCEPTIONAL ITEMS/ PRIOR PERIOD ITEMS</b>	-	-	-	-	-
<b>5. PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (3-4)</b>	<b>3.62</b>	<b>0.87</b>	<b>12.27</b>	<b>4.49</b>	<b>27.44</b>
<b>6. TAX EXPENSES</b>	(2.20)	(2.50)	2.60	(4.70)	6.97
-CURRENT TAX	(0.29)	0.29	2.63	-	7.29
-TAX ADJUSTMENTS RELATING TO EARLIER YEARS	-	-	-	-	-
-DEFERRED TAX (NET)	(1.91)	(2.79)	(0.03)	(4.70)	(0.32)
<b>7. NET PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (5-6)</b>	<b>5.82</b>	<b>3.37</b>	<b>9.67</b>	<b>9.19</b>	<b>20.47</b>
<b>8. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS</b>	-	-	-	-	-
<b>9. TAX EXPENSES FOR DISCONTINUED OPERATIONS</b>	-	-	-	-	-
<b>10. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS (AFTER TAX) (8-9)</b>	-	-	-	-	-
<b>11. PROFIT/(LOSS) FOR THE PERIOD (7+10)</b>	<b>5.82</b>	<b>3.37</b>	<b>9.67</b>	<b>9.19</b>	<b>20.47</b>
<b>12. OTHER COMPREHENSIVE INCOME</b>					
A. (i) ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS					
(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS					
B. (i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS	(3.25)	(4.57)	-	(7.82)	-
(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS					
<b>13. TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (11+12) (COMPRISING PROFIT (LOSS) AND OTHER COMPREHENSIVE INCOME)</b>	<b>2.57</b>	<b>(1.20)</b>	<b>9.67</b>	<b>1.37</b>	<b>20.47</b>
<b>14. EARNINGS PER EQUITY SHARE (FOR CONTINUING OPERATION)</b>					
(i) BASIC	0.07	0.04	0.12	0.11	0.25
(ii) DILUTED	0.07	0.04	0.12	0.11	0.25
<b>15. EARNINGS PER EQUITY SHARE (FOR DISCONTINUING OPERATION) :</b>					
(i) BASIC	-	-	-	-	-
(ii) DILUTED	-	-	-	-	-
<b>16. EARNINGS PER EQUITY SHARE (FOR CONTINUING AND DISCONTINUING OPERATION) :</b>					
(i) BASIC	0.07	0.04	0.12	0.11	0.25
(ii) DILUTED	0.07	0.04	0.12	0.11	0.25

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956





**TRIMURTHI LIMITED**  
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)

Segment Reporting

	PARTICULARS	QUARTER ENDED			HALF YEARLY ENDED	
		30.09.2018 (UNAUDITED)	30.06.2018 (UNAUDITED)	30.09.2017 (UNAUDITED)	30.09.2018 (UNAUDITED)	30.09.2017 (UNAUDITED)
1.	<b>Segment Revenue</b>					
	a. Pharma Business	0.00	0.00	0.00	0.00	0.00
	b. Financial Services	13.83	16.98	21.64	30.81	43.02
	c. Investments	2.08	0	0.00	2.08	0.00
	d. Trading in Shares	6.00	11.27	5.52	17.27	37.13
	e. Foods	86.67	77.05	0.00	163.72	0.00
	<b>Total</b>	<b>108.58</b>	<b>105.30</b>	<b>27.16</b>	<b>213.88</b>	<b>80.15</b>
	Less: Inter Segment Revenue	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
	<b>Net Sales/ Income From Operations</b>	<b>108.58</b>	<b>105.30</b>	<b>27.16</b>	<b>213.88</b>	<b>80.15</b>
2.	<b>Segment Profits ( Before tax &amp; Interest From Each Segment)</b>					
	a. Pharma Business	0.00	0	0.00	0.00	0.00
	b. Financial Services	11.19	13.64	14.62	24.83	30.25
	c. Investments	2.08	0	0.00	2.08	0.00
	d. Trading in Shares	4.94	1.78	(2.49)	6.72	(2.94)
	e. Foods	(14.60)	(14.55)	0.00	(29.15)	0.00
	<b>Total</b>	<b>3.62</b>	<b>0.87</b>	<b>12.13</b>	<b>4.49</b>	<b>27.31</b>
	Less:					
	i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
	ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
	iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
	<b>Total Profit Before Tax</b>	<b>3.62</b>	<b>0.87</b>	<b>12.13</b>	<b>4.49</b>	<b>27.31</b>
3.	<b>Capital Employed</b>					
	a. Pharma Business	0.00	0	0.00	0.00	0.00
	b. Financial Services	(9.66)	531.84	(33.82)	522.18	645.15
	c. Investments	(40.81)	312.82	0.00	272.01	184.34
	d. Trading in Shares	41.76	315.54	46.24	357.30	351.98
	e. Foods	12.33	19.78	0.00	32.11	0.00
	<b>Total</b>	<b>3.63</b>	<b>1179.98</b>	<b>12.42</b>	<b>1183.61</b>	<b>1181.47</b>

Notes:


- The format for the Unaudited quarterly results as prescribed in SEBI Circular CRI/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with the requirements of SEBI Circular CRI/CFD/FAC/62/2016 dated July 5, 2016.
- Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- The financial results were reviewed by the Audit Committee and then approved at the meeting of the Board of Directors of the Company held on 14th November 2018. The limited review of the financial results for the Quarter ended 30th September 2018 has been carried out by the statutory auditors of the Company.
- The above standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34- Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India.

For and on behalf of the Board

Place : Hyderabad  
Date : 14th September, 2018.

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956







**TRIMURTHI**  
GROUP

**TRIMURTHI LIMITED**

(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)

**Standalone Assets and Liabilities for the half year ended 30th September 2018**

	Particulars	As at	As at
		30-09-2018	31-03-2018
		(Rs In Lakhs)	(Rs In Lakhs)
<b>ASSETS</b>			
1	<b>Non-Current assets</b>		
	a) Property, Plant and Equipment	54.67	59.62
	b) Capital Work In Progress	-	-
	c) Investment Property	-	-
	d) Other Intangible Assets	1.01	1.66
	e) Financial Assets		
	(i) Investments	272.01	292.00
	(ii) Trade Receivables	-	-
	(iii) Loans	-	-
	(iv) Other Financial Assets	-	-
	f) Deferred Tax Assets (Net)	-	-
	g) Other Non Current Assets	20.90	20.90
	Sub-total: Non-Current Assets	<b>348.59</b>	<b>374.18</b>
2	<b>Current assets</b>		
	Inventories	3.14	11.12
	Financial Assets		
	(i) Investments	-	-
	(ii) Trade Receivables	171.53	111.15
	(iii) Cash & Cash Equivalents	9.04	15.31
	(iv) Bank Balances other than (iii) above	-	-
	(v) Loans	499.37	521.58
	(vi) Others (to be specified)	199.77	192.60
	Sub-total: Current Assets	<b>882.84</b>	<b>851.75</b>
	<b>Total Assets</b>	<b>1,231.43</b>	<b>1,225.93</b>
<b>EQUITY AND LIABILITIES</b>			
1	<b>Equity</b>		
	a) Equity Share Capital	810.00	810.00
	b) Other Equity	373.61	372.24
	Sub-total: Equity	<b>1,183.61</b>	<b>1,182.24</b>
2	<b>Liabilities</b>		
	<b>Non-Current Liabilities</b>		
	a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade Payables	-	-
	(iii) Other Financial Liabilities	-	-
	b) Provisions	-	-
3	c) Deferred Tax Liabilities (Net)	(0.68)	4.02
	d) Other Non Current Liabilities	-	-
	Sub-total: Non-Current Liabilities	<b>(0.68)</b>	<b>4.02</b>
	<b>Current Liabilities</b>		
	a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade Payables	45.45	31.09
	(iii) Other Financial Liabilities	-	-
	b) Other Current Liabilities	3.05	7.49
	c) Provisions	-	-
	d) Current Tax Liabilities (Net)	-	1.09
	Sub-total: Current Liabilities	<b>48.50</b>	<b>39.67</b>
	<b>Total Equity and Liabilities</b>	<b>1,231.43</b>	<b>1,225.93</b>

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956







## P. MURALI & CO.,

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA


Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

### Limited Review Report- Standalone Financial Results

To  
The Board of Directors,  
**Trimurthi Limited** (Formerly known as Trimurthi Drugs & Pharmaceuticals Limited),  
Hyderabad,  
India.

Limited Review Report for the Quarter and Half year ended 30<sup>th</sup> September, 2018.

1. We have reviewed the accompanying statement of unaudited standalone financial results of Trimurthi Limited (the 'Company') for the quarter ended 30<sup>th</sup> September, 2018 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/ 62/2016 dated July 5, 2016.
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015, read with SEBI Circular No. CIR/CFD/ FAC/62/ 2016 dated July 5, 2016 is the responsibility of the Company's management and has been approved by the Board of Directors of the Company in their meeting held on 14<sup>th</sup> November, 2018. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and policies







**P. MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/ 62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.  
Chartered Accountants  
FRN: 007257S

  
M V JOSHI  
Partner  
M.No : 024784



Place: Hyderabad  
Date: 14.11.2018